Circassia Limited Seeks $285 Million In One Of Europe's Biggest Biotech IPOs
06 Feb 2014
Vaccine
Circassia, a company developing allergy treatments based on a discovery by scientists at Imperial College in London, aims to raise about 175 million pounds ($285 million) of new funds in one of Europe's biggest biotechnology IPOs. The stock market debut in London will help to bring its cat allergy vaccinecat allergy vaccine to market. Chief executive and co-founder Steve Harris said the proceeds of the flotation in London would also support the firm's programmes in other common allergies such as house dust mites, grass and ragweed.
Help employers find you! Check out all the jobs and post your resume.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.